HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $70 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein reiterates a Buy rating on Insmed (NASDAQ:INSM) and maintains a $70 price target.
July 02, 2024 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterates a Buy rating on Insmed and maintains a $70 price target.
The reiteration of a Buy rating and the maintenance of a $70 price target by a reputable analyst can boost investor confidence in Insmed, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100